Fornasiero Massimiliano, Geropoulos Georgios, Kechagias Konstantinos S, Psarras Kyriakos, Katsikas Triantafyllidis Konstantinos, Giannos Panagiotis, Koimtzis Georgios, Petrou Nikoletta A, Lucocq James, Kontovounisios Christos, Giannis Dimitrios
Medical School, University College London, London WC1E 6BT, UK.
2nd Propaedeutic Department of Surgery, Aristotle University School of Medicine, Hippokration General Hospital, 546 42 Thessaloniki, Greece.
Cancers (Basel). 2022 Nov 7;14(21):5464. doi: 10.3390/cancers14215464.
Anastomotic leaks (AL) following ovarian cytoreduction surgery could be detrimental, leading to significant delays in commencing adjuvant chemotherapy, prolonged hospital stays and increased morbidity. The aim of this study was to investigate risk factors associated with anastomotic leaks after ovarian cytoreduction surgery.
The MEDLINE (via PubMed), Cochrane Library, EMBASE and Scopus bibliographical databases were searched. Original clinical studies investigating risk factors for AL in ovarian cytoreduction surgery were included.
Eighteen studies with non-overlapping populations reporting on patients undergoing cytoreduction surgery for ovarian cancer (n = 4622, including 344 cases complicated by AL) were included in our analysis. Patients undergoing ovarian cytoreduction surgery complicated by AL had a significantly higher rate of 30-day mortality but no difference in 60-day mortality. Multiple bowel resections were associated with an increased risk of postoperative AL, while no association was observed with body mass index (BMI), American Society of Anesthesiologists (ASA) score, age, smoking, operative approach (primary versus interval cytoreductive, stapled versus hand-sewn anastomoses and formation of diverting stoma), neoadjuvant chemotherapy and use of hyperthermic intraperitoneal chemotherapy (HIPEC).
Multiple bowel resections were the only clinical risk factor associated with increased risk for AL after bowel surgery in the ovarian cancer population. The increased 30-day mortality rate in patients undergoing ovarian cytoreduction complicated by AL highlights the need to minimize the number of bowel resections in this population. Further studies are required to clarify any association between neoadjuvant chemotherapy and decreased AL rates.
卵巢肿瘤细胞减灭术后吻合口漏(AL)可能有害,会导致辅助化疗开始时间显著延迟、住院时间延长及发病率增加。本研究旨在调查卵巢肿瘤细胞减灭术后与吻合口漏相关的危险因素。
检索了MEDLINE(通过PubMed)、Cochrane图书馆、EMBASE和Scopus书目数据库。纳入了调查卵巢肿瘤细胞减灭术中AL危险因素的原始临床研究。
我们的分析纳入了18项针对不同人群的研究,这些研究报告了接受卵巢癌肿瘤细胞减灭术的患者(n = 4622,包括344例并发AL的病例)。并发AL的卵巢肿瘤细胞减灭术患者30天死亡率显著更高,但60天死亡率无差异。多次肠切除术与术后AL风险增加相关,而未观察到与体重指数(BMI)、美国麻醉医师协会(ASA)评分、年龄、吸烟、手术方式(初次与间隔肿瘤细胞减灭术、吻合器与手工缝合吻合以及造口形成)、新辅助化疗和热灌注化疗(HIPEC)的使用有关。
多次肠切除术是卵巢癌患者肠道手术后与AL风险增加相关的唯一临床危险因素。并发AL的卵巢肿瘤细胞减灭术患者30天死亡率增加凸显了在该人群中尽量减少肠切除数量的必要性。需要进一步研究以阐明新辅助化疗与降低AL发生率之间的任何关联。